Thymidine kinase 1 expression in atypical ductal hyperplasia significantly differs from usual ductal hyperplasia and ductal carcinoma in situ: A useful tool in tumor therapy management

Molecular Medicine Reports

Volumn 2, Issue 6, 2009, Pages 923-929

  Guan, Hong ^a   Sun, Yanhua ^a   Zan, Qin ^a   Xu, Meiquan ^a   Li, Yuan ^b   Zhou, Ji ^b   He, Ellen ^b   Eriksson, Staffan ^c   Wen, Wen ^a   Skog, Sven ^b  

^a Shenzhen Second Hospital   (China)

^b Sino Swed Molecular Bio Medicine Research Institute   (China)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Atypical ductal hyperplasia; Ductal breast cancer; Ductal carcinoma in situ; Immunohistochemistry; Invasive ductal carcinoma; Ki 67; Thymidine kinase 1; Usual ductal hyperplasia

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY; THYMIDINE KINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CARCINOMA; BREAST DUCT; BREAST HYPERPLASIA; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; EARLY CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRECANCER; PRIMARY TUMOR; PROTEIN EXPRESSION; STAINING; SURVIVAL TIME;

EID: 73649119916     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr-00000193     Document Type: Article

References (34)

1. Glück S, McKenna EF Jr and Royce M: XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancer. Int J Med Sci 5: 341-346, 2008.
2. Torris R, Bagnardi V, Cardillo A, et al: Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 18: 1564-1571, 2008.
3. Prati R, Minami CA, Gornbein JA, et al: Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy. Cancer 115: 1194-1202, 2009.
4. Fleming ID, Cooper JS, Henson DE, et al (eds): Breast. In: AJCC Cancer Staging Manual. 5th edition. Lippincott-Raven Publishers, Philadelphia, pp171-211, 1995.
5. Tavassoli FA and Devilee P: WHO Organization Classification of Tumors, Pathology and Genetics, Tumors of the Breast and Female Genital Organs. World Health Organization, p16, 2002.
6. He E, Mao Y, Wu J, et al: Cytosolic thymidine kinase is a specific histopathologic tumor marker for breast carcinomas. Int J Oncol 25: 945-953, 2004.
7. Wu C, Yang R, Zhou J, et al: Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277: 157-169, 2003.
8. Törnevik Y, Ullman B, Balzarini J, et al: Cytotoxicity of 3'-azido-3'-deoxythymidine correlates with 3'-azidothymidine-5'-monophosphate (AZTMP) levels, whereas anti-human immunodeficiency virus (HIV) activity correlates with 3'-azidothymidine 5'-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 49: 829-837, 1995.
9. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 406: 747-752, 2000.
10. Ahr A, Holtrich U, Solbach C, et al: Molecular classification of breast cancer patients by gene expression profiling. J Pathol 195: 312-320, 2001.
11. ASCO: Recommendations of the American Society of Clinical Oncology. A patient's guide: understanding tumor markers for breast and colorectal cancers. American Society of Clinical Oncology, pp1-7, 2002.
12. Beresford MJ, Wilson GD and Makris A: Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 8: 216, 2006.
13. Pegram M and Slamon D: Biological relation for Her/neu (c- erbB2) as a target for monoclonal antibody therapy. Semin Oncol 9: 13-19, 2000.
14. Aziz S, Pervez S, Khan S, et al: Case control study of novel prognostic markers and diseases outcome pregnancy/lactation-associated breast carcinoma. Pathol Res Pract 199: 15-21, 2003.
15. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
16. Eissa S: Tumor Markers. Chapman & Hall Medical, New York, pp94-102; pp134-137, 1998.
17. Beenken SW and Bland KI: Biomarker for breast cancer. Minerva Chir 57: 437-448, 2002.
18. Zacchetti A, van Garderen E, Teske E, et al: Validation of the use of proliferation markers in canine neoplastic and non-neoplastic tissues: comparison of Ki-67 and proliferating cell nuclear antigen (PCNA) expression versus in vivo bromodeoxyuridine labeling by immunohistochemistry. APMIS 111: 430-438, 2003.
19. Faneyte IF, Schrama JG, Peterse JL, et al: Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer. 88: 406-412, 2003.
20. Sherley JL and Kelly TJ: Regulation of human thymidine kinase during the cell cycle. J Biol Chem 26: 8350-8358, 1988.
21. Sherley JL and Kelly TJ: Human cytosolic thymidine kinase. Purification and physical characterization of the enzyme from HeLa cells. J Biol Chem 263: 375-382, 1988.
22. He Q, Skog S and Tribukait B: Cell cycle related studies on thymidine kinase and its isoenzymes in Ehrlich ascites tumors. Cell Prolif 24: 3-14, 1991.
23. Kauffman MG and Kelly TJ: Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol 11: 2538-2546, 1991.
24. Hengstschläger M, Knöfler M, Müllner EW, et al: Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem 19: 13836-13842, 1994.
25. He Q, Wang N, Skog S, et al: Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol 70: 117-124, 1996.
26. Schwartz GF, Schwarting R, Rabindranauth P, et al: Clinical application of serum and tissue markers in malignant disease: breast cancer as the paradigm. Clin Chem 39: 2401-2412, 1993.
27. Broet P, Romain S, Daver A, et al: Thymidine kinase as a proliferative marker: clinical relevance in 1,692 primary breast cancer patients. J Clin Oncol 19: 2778-2787, 2000.
28. Romain S, Christensen IJ, Chinot O, et al: Prognostic value of cytosolic thymidine kinase activity as marker of proliferation in breast cancer. Int J Cancer 61: 7-12, 1995.
29. Romain S, Martin PM and Klijin JG: DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer. Int J Cancer 74: 156-161, 1997.
30. Spyratos F, Martin PM, Hacene K, et al: Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst 84: 1266-1272, 1992.
31. He Q, Zou L, Zhang P, et al: The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. Int J Biol Marker 15: 139-146, 2000.
32. He Q, Fornander T, Johansson H, et al: Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Res 26: 4753-4759, 2006.
33. Mao YR, Wu JP, Wang N, et al: Comparison study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest 20: 922-931, 2002.
34. Okumura Y, Yamamoto Y, Zhang Z, et al: Identification of biomarkers in ductal carcinoma in situ of breast with microinvasion. BMC Cancer 6: 287, 2008.